Silk Technologies

Recent Finacing

Series A ext

Recent Raise

$6.2M

SilkTech Biopharmaceuticals develops silk-derived protein therapeutics with patented SDP technology from Bombyx mori, producing SDP-4 investigational eye drops (dual anti-inflammatory and wetting actions) in Phase 2 for dry eye.

Founded 2013

Minnesota, United States

11-50

Private

silk-tech.com

Highlights

Focus Areas

Biotechnology

Health Care

Hospital

Recent Investors

Financials

$17.4M

Total Raised

2

Funding rounds

1

Investor

Team

Upgrade to view the team

See the team members at Silk Technologies.